drugset / Trial / NCT00560391
Dasatinib in Combination With Revlimid (and Dexamethasone)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Timeline
- Start
- 2008-05
- Primary completion
- 2011-10
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 70 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | — |
| Subject | dasatinib anhydrous | Small molecule | 140 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |